Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INO-5401 + Rocakinogene sifuplasmid |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INO-5401 | INO5401|INO 5401 | INO-5401 is a DNA plasmid engineered to encode for WT1, hTERT, and PSMA, which potentially enhances antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2004, Journal for ImmunoTherapy of Cancer 2020;8). | ||
Rocakinogene sifuplasmid | INO9012|INO 9012|INO-9012 | Rocakinogene sifuplasmid (INO-9012) is a plasmid encoding the IL-12 protein subunits p35 and p40, which may increase antitumor immune response and decrease tumor growth (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT114, PMID: 32208168). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04367675 | Phase I | INO-5401 INO-5401 + Rocakinogene sifuplasmid | INO 5401 Vaccination in BRCA1/2 Mutation Carriers | Recruiting | USA | 0 |